Oncology Data Advisor
Enfortumab Vedotin Plus Pembrolizumab: Results of the EV-302 Trial With Thomas Powles
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:11:39
- Mas informaciones
Informações:
Sinopsis
In this interview, Thomas Powles, MD, MBBS, MRCP, Director of the Barts Cancer Center in London, sat down with Oncology Data Advisor to discuss the results of the EV-302 trial, a phase 3, open-label investigation of enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial cancer.
